【藥品訊息】 Ultilbro吸入劑 衛教單張

慢性阻塞性肺病 COPD
Maintenance treatment in patients with chronic obstructive pulmonary disease

Indacaterol: Beta₂-Adrenergic Agonist, Long-Acting
Relaxes bronchial smooth muscle by selective action on beta2-receptors with little effect on heart rate; acts locally in the lung.
Glycopyrronium: Anticholinergic Agent
In COPD, competitively and reversibly inhibits the action of acetylcholine at muscarinic receptor subtypes 1 and 3 in bronchial smooth muscle thereby causing bronchodilation.

Onset of action: within 5 minutes after dosing.
Duration: 24 hours

1. Hypersensitivity to indacaterol maleate, or glycopyrronium bromide, or any component of the formulation
2. Severe hypersensitivity to milk proteins

C

Excretion in breast milk unknown/use caution

Nasopharyngitis, upper respiratory tract infection, dry mouth

Oral inhalation:
Contents of 1 capsule (indacaterol 110 mcg/glycopyrronium 50 mcg) inhaled once daily using Ultibro Breezhaler device.
Note:
1. Dose delivered per capsule is equivalent to indacaterol 85 mcg/glycopyrronium 43 mcg
2. Not to be used for the relief of acute attacks
3. Administer once daily at the same time each day